Nanofármacos

BEAD BOUND ANTICD28 ANTIBODY FOR THE TREATMENT OF MALIGNANT MELANOMA

Resumen de: WO2024121164A1

The present invention relates to solid microbeads having an anti-CD28 monoclonal antibody immobilized thereto for use in the local treatment of malignant melanoma, wherein the anti-CD28 monoclonal antibody binds to an epitope on CD28 outside the C" D loop. The present invention further relates to methods for the local treatment of malignant melanoma comprising the administration of said microbeads.

PROTEIN NANOPELLETS FOR FISH OR TELEOST AND CRUSTACEAN VACCINATION

Resumen de: WO2024121028A1

Protein nanopellets for fish or teleost and crustacean vaccination The present invention relates to protein nanopellets comprising one or more polypeptides comprising the amino acid sequence of an interferon or a fragment thereof, the amino acid sequence of a viral antigen or a fragment thereof and, optionally, a linker between them; and with a particle diameter from 400 nm to 1500 nm, measured by electron microscopy. It also discloses their use in immunogenic compositions and vaccines to immunize fish or teleost and crustacean against several virus diseases.

IONIZABLE LIPIDS WITH MALONATE TAILS

Resumen de: WO2024123978A1

The present disclosure provides new ionizable lipids, lipid nanoparticle (LNP) compositions comprising the same, and methods of delivering therapeutic and/or prophylactic agents (e.g., mRNA) with the LNPs described herein. The ionizable lipids described herein comprise a central nitrogen atom bonded to (i) a head group; and (ii) two biodegradable, hydrophobic lipids tails, wherein at least one biodegradable lipid tail comprises a malonate moiety. Ionizable lipids described herein include compounds of Formula (I) and pharmaceutically acceptable salts thereof.

IMMUNOGENIC COMPOSITIONS AGAINST INFLUENZA AND RSV

Resumen de: TW202430642A

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and/or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

COMPOSITIONS AND METHODS FOR PEPTIDE OR PROTEIN DELIVERY TO THE DELIVERY TO THE CENTRAL NERVOUS SYSTEM

Resumen de: US2025288534A1

The present disclosure provides a lipid nanoparticle to treat, prevent or diagnose a central nervous system disease, disorder, trauma or injury, the lipid nanoparticle comprising: a non-cationic helper lipid; a sterol; a hydrophilic polymer-lipid conjugate; an ionizable, amino amino lipid having a pKa between 5.0 and 7.0; and an mRNA having a nucleic acid sequence encoding for a secretory polypeptide for treating, preventing or diagnosing the central nervous system disease, disorder, trauma or injury, the secretory polypeptide being capable of secretion from a cell of the central nervous system into a interstitial and/or cerebrospinal fluid of a subject. Further provided are methods for administration of the lipid nanoparticles to treat, prevent or diagnose the central nervous system disease, disorder, trauma or injury and uses of such lipid nanoparticles.

COMPOSITION FOR USE IN LOWERING BLOOD GLUCOSE LEVEL

Resumen de: EP4631519A1

A composition containing a Momordica charantia-derived exosome and a Momordica charantia insulin receptor-binding protein for use in lowering blood glucose level in a subject in need thereof. A weight ratio of the Momordica charantia-derived exosome to the Momordica charantia insulin receptor-binding protein ranges from 2:1 to 5:1. The composition is a food product or a pharmaceutical composition.

NANOPARTICLE COMPRISING PEPTIDE-BASED CONJUGATE FOR DELIVERING MRNA INTO B CELL AND T CELL AND USES THEREOF

Resumen de: EP4631527A1

The present invention relates to a peptide-based conjugate for mRNA delivery, which overcomes the limitations of existing lipid nanoparticles and is capable of safely and immediately responding to new variants of infectious diseases. mRNA binds to an RNA-binding peptide of the conjugate and undergoes self-assembly by an amphipathic polypeptide or polymer to thereby form a peptide and mRNA complex nanoparticle. The nanoparticle and a pharmaceutical composition comprising same were confirmed to efficiently increase intracellular delivery of mRNA and exhibit a vaccine effect by mRNA.

NANOPARTICLE COMPRISING PEPTIDE-BASED CONJUGATE FOR DELIVERING OLIGONUCLEOTIDE INTO TARGET CELL AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

Resumen de: EP4631528A1

The present invention relates to: a carrier for delivering oligonucleotides intended for therapeutic use into cells, wherein, to inhibit a target protein or promote expression of a target protein in a cell, a peptide-based conjugate is prepared, and a nanoparticle consisting of a peptide-based conjugate comprising oligonucleotides; and a pharmaceutical composition comprising the carrier. It was confirmed that, by using the nanoparticle consisting of the peptide-based conjugate according to the present invention, oligonucleotides were effectively delivered into cells. In addition, by confirming that the expression of a cancer-causing protein is reduced by oligonucleotides and that an anticancer effect is exhibited in an animal model in which cancer has occurred, the nanoparticle consisting of the peptide-based conjugate was found to be effective in the delivery of oligonucleotides.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

Resumen de: MX2025006631A

Provided are aerosolized pharmaceutical compositions including aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs). Also provided herein are liquid pharmaceutical compositions for use in making aerosolized pharmaceutical compositions. Also provided herein are methods of administering the aerosolized pharmaceutical compositions. Also provided herein are kits including a lipid nanoparticle composition including one or more of a phospholipid, an ionizable lipid, a PEG-lipid, a sterol.

EDIBLE CANNABIS PLANT POWDER

Resumen de: US2024189379A1

A composition of matter comprising an edible organically based substance, as well as an apparatus and method of making the composition of matter is disclosed. In one embodiment, the composition of matter, apparatus and method are directed to an edible organically based powder comprising an organic material, MCT oil, and MCT oil powder. In certain embodiments, the organic material and MCT oil are mixed together, heated and agitated binding the MCT oil to the organic material and decarboxylating the compound. The decarboxylated compound is then cooled. The decarboxylated compound is then ground to a desired size (which in some embodiments may be as fine as a powder) which is then mixed with MCT oil powder to produce the edible organic substance. In certain embodiments, the organic material comprises cannabis, and the resulting edible organic substance resulting from the disclosed process is an edible cannabis plant powder.

PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION

Resumen de: WO2024123461A1

Provided herein are compositions and methods for treating retinal degeneration, such as an inherited retinal degeneration. In some examples, the compositions include a pigment epithelium-derived factor (PEDF) protein or a peptide thereof. Compositions including a PEDF 17merH105A peptide in an eye drop formulation or an adeno-associated virus vector including a nucleic acid encoding a PEDF protein or PEDF 17merH105A peptide are provided. Methods for treating retinal degeneration include administering a provided eyedrop formulation or adeno-associated virus vector to an eye of a subject with retinal degeneration.

LIPID NANOPARTICLES COMPRISING ELEVATED NEUTRAL LIPID AND A TARGETING MOIETY FOR TARGETED DELIVERY OF NUCLEIC ACID

Resumen de: AU2023387789A1

Provided herein is a lipid nanoparticle encapsulating nucleic acid and having at least 30 mol% neutral lipid, a sterol or derivative thereof and a targeting moiety anchored in a lipid layer thereof via a lipophilic moiety. Further provided are methods of using the lipid nanoparticles for targeted delivery in vivo. Such lipid nanoparticle may exhibit significantly improved delivery and targeting to extrahepatic tissues and/or organs.

一种降尿酸组合物及其制备方法

Resumen de: CN120771238A

本发明涉及中药技术领域，尤其涉及一种降尿酸组合物及其制备方法。该降尿酸组合物，包括环糊精包合物35‑45份，纳米脂质体25‑35份，菊苣提取物‑磷脂复合物20‑30份，抗氧化复合物5‑8份；所述环糊精包合物的制备方法为：步骤1，将β‑环糊精加入水中，搅拌并溶解并加入葛根提取物，包合反应后干燥，得包合物a；步骤2，将羟丙基‑γ‑环糊精加入水中，搅拌并加入桑叶提取物，包合作用后干燥，得包合物b；步骤3，将包合物a和包合物b混合，即得。本发明的降尿酸组合物，更全面、高效地降低血尿酸水平，且安全性高、稳定性强、生物利用度高。本发明的制备方法简便且易于产业化，利于大规模工业化生产。

一种抑制PCSK9基因表达的干扰RNA及其应用

Resumen de: CN120775842A

本发明公开了一种抑制PCSK9基因的干扰RNA及其应用。所述干扰RNA包含SEQ ID NO:1～40、73～96中的任一个或两个以上所示的核苷酸序列。本发明的干扰RNA可以更好地靶向肝脏PCSK9的mRNA并使其沉默，降低PCSK9的蛋白水平，增强LDL‑C代谢，降低血清胆固醇，为由PCSK9基因介导疾病的预防、治疗和症状缓解的siRNA药物的研发提供坚实的技术基础。

一种流感mRNA疫苗及其制备方法

Resumen de: CN120775884A

本发明涉及一种流感病毒mRNA疫苗，所述mRNA疫苗编码包含流感病毒血凝素蛋白(HA)或其功能片段和Fc或其变体的融合蛋白。所述mRNA疫苗能够通过表达流感血凝素蛋白(HA)和Fc或其变体融合蛋白提升流感病毒HA抗原的免疫原性和功能性抗体的滴度。本发明所制备得到的流感病毒mRNA疫苗在低剂量下即可诱导机体产生高水平、长效的免疫应答，可以实现临床上降低给药剂量，并在流感季、大流行流感爆发时快速进行疫苗供应。

核酸-脂质颗粒

Resumen de: MX2025006743A

The present invention pertains to a composition comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of nucleic acids in the lipid bilayer. The present invention furthermore pertains to said composition, for use in preventing and/or treating a disease, in particular for use in preventing and/or treating cancer. The present invention furthermore pertains to a method for producing a composition comprising said nucleic acid-lipids particles.

一种肺靶向脂质纳米颗粒的构建及应用

Resumen de: CN120774809A

本发明涉及肺靶向药物递送技术领域，涉及肺靶向类脂分子化合物及其脂质纳米颗粒的制备方法与应用。通过肺靶向类脂分子化合物的精准合成和基于该类化合物的肺靶向脂质纳米颗粒的制备，本发明成功开发了一种新型脂质纳米载体药物递送系统。该系统主要由创新合成的类脂分子、辅助脂质和稳定剂等组分构成，形成了结构稳定、靶向性强的纳米递送平台。实验证实，该系统能够高效包载治疗药物，包括脂溶性和水溶性的大分子和小分子，尤其是mRNA，并实现对肺部组织的精准递送，显著提高药物在靶器官的富集度，同时减少药物在非靶向组织的分布，其靶向肺组织的关键因素在于其在血液系统中形成的特异蛋白冠。

一种ROS响应的核壳共递送纳米药物载体及其制备方法

Resumen de: CN120771128A

本发明公开了一种ROS响应的核壳共递送纳米药物载体，以ROS响应的核壳共递送纳米药物载体的重量百分比计，包括22‑32wt%的介孔二氧化硅纳米颗粒为核心，核心内部装载有2‑10wt%的2‑(1,1‑联苯‑4‑基氨基甲酰)苯甲酸，核心表面嵌入15‑20wt%的超小普鲁士蓝形成超小普鲁士蓝层，超小普鲁士蓝层之外包覆50‑60wt%的硒化透明质酸层构成的外壳，所述的ROS响应的核壳共递送纳米药物载体的平均粒径为80‑110nm。本发明的ROS响应的核壳共递送纳米药物载体具有有序的结构，超小普鲁士蓝不仅能适当阻断介孔二氧化硅纳米颗粒的孔入口，而且能增加其抗氧化能力。硒化透明质酸层进一步增强了药物负载效率防止药物渗漏，同时赋予软骨靶向性和ROS反应性以控制药物释放，提高药物的稳定性和生物利用度。

一种可精准质控的干细胞纳米囊泡及其应用

Resumen de: CN119530147A

The invention relates to a stem cell bioactive nano-vesicle with efficient inflammation regulation and tissue repair effects, the average particle size of the nano-vesicle is 100-350nm, the polydispersity index (PDI) is 0.05-0.40, and the expression rate of phosphatidylserine (PS) on the surface of the nano-vesicle is greater than 40%. According to the preparation method, stem cells are subjected to apoptosis induction, and then a programmed serial extrusion process is adopted to prepare the nano-vesicles. The nano vesicles are moderate in particle size, uniform in distribution and high in production efficiency, the preparation process is easy to operate, the quality is stable and controllable, and the nano vesicles have excellent technical effects in the aspects of repair and regeneration of inflammation injury type tissues and organs.

剪切力响应性纳米粒子靶向递送FBPi在防治钙化性主动脉瓣膜病中的用途

Resumen de: CN120771287A

本发明公开了一种剪切力响应性纳米粒子靶向递送FBPi在防治钙化性主动脉瓣膜病中的用途，涉及医学生物工程技术领域。本发明通过研究明确了巨噬细胞的胞葬作用如何调节CAVD中的成骨重编程知识；明确了抑制FBP1增强巨噬细胞胞葬作用减轻CAVD；构建了有效靶向主动脉瓣FBP1的剪切力响应性纳米粒子靶向递送药物用于治疗CAVD，解决了部分CAVD机制问题以及目前尚无有效主动脉瓣FBP1靶向药物用于治疗CAVD的核心问题。实验数据表明剪切力响应性纳米粒子靶向递送FBPi增强巨噬细胞胞葬作用减轻主动脉瓣钙化。这一完整策略不仅为钙化性主动脉瓣疾病提供了新的药物靶点治疗方法，也为其他血管疾病的治疗提供了新策略。

一种用于调节免疫的双膜独立包裹纳米递药系统的制备与应用

Resumen de: CN120771127A

本发明公开了一种用于调节巨噬细胞及血小板的双膜独立包裹纳米递药系统。该纳米递药系统包括调节巨噬细胞免疫反应的载有Toll样受体7（TLR7）抑制剂的巨噬细胞膜包裹纳米粒及抑制血小板异常活化的载有G蛋白偶联受体P2Y12抑制剂的血小板膜包裹纳米粒，所述的TLR7抑制剂包括TJ‑M2010‑5、羟氯喹、Enpatoran、IMO‑8400中的至少一种，所述的P2Y12抑制剂包括替格瑞洛、氯吡格雷、普拉格雷、坎格雷洛中的至少一种。本发明所述的双膜独立包裹纳米递药系统，利用两种细胞膜的相关细胞趋向性将药物高效递送至炎症部位的相关受损细胞，抑制了巨噬细胞及血小板异常所导致的免疫紊乱，治疗由于免疫失衡所诱发的疾病，调控免疫微环境，为免疫性疾病的治疗提供新方向。

用于递送核酸载物的纳米颗粒

Resumen de: AU2024213893A1

Nanoparticles suitable for delivery of a linear DNA molecule are provided. Nanoparticles suitable for delivery of mRNA or DNA are provided. Further provided are uses of the nanoparticles including the use of the nanoparticles for treating disease and the use of the nanoparticles in vaccines.

一种多模式协同增效纳米颗粒及其制备方法和应用

Resumen de: CN120771304A

本发明属于乳腺癌技术领域，具体涉及一种多模式协同增效纳米颗粒及其制备方法和应用，纳米颗粒包括沸石咪唑酯骨架材料8，沸石咪唑酯骨架材料8内包载有青蒿琥酯和葡萄糖氧化酶，制备方法包括：称取青蒿琥酯溶于N,N‑二甲基甲酰胺溶液中得到药物储备浓溶液，称取二甲基咪唑溶于去离子水中，称取六水合硝酸锌溶于去离子水中，将称好的葡萄糖氧化酶以及青蒿琥酯的储备浓溶液加入到二甲基咪唑溶液中搅拌，随后再加入六水合硝酸锌溶液，继续搅拌，得到混悬液，离心得到沉淀，水洗离心收集最终产物ART/GOx@ZIF‑8，本发明克服单一化疗药物的耐药性，能够实现多模式协同治疗、同时调节或利用肿瘤微环境，具有重要的研究意义和应用价值。

治疗高降钙素原血症的组合物和方法

Resumen de: MX2025008776A

A composition for treating hyperprocalcitonemia is described. The composition comprises a lipophilic or hydrophobic component, an amphiphilic emulsifier, a polar liquid carrier, and with or without one or more electrolytes, where the amphiphilic emulsifier forms micelles having a lipophilic or hydrophobic core comprising the lipophilic or hydrophobic component in the polar liquid carrier, and /or liposomes organized as a lipid bilayer and/or other particle configurations.

一种他达那非超分子纳米颗粒及其制备方法

Nº publicación: CN120771305A 14/10/2025

Solicitante:

安徽省诚联医药科技有限公司

Resumen de: CN120771305A

本发明提供一种他达那非超分子纳米颗粒及其制备方法，涉及医疗技术领域。该他达那非超分子纳米颗粒，包括由微纤维骨架、原位分子胶和载药体组分构成的颗粒：所述颗粒的载药率需大于58％，且具有六边形孔道排列结构，所述微纤维骨架为脱木质素率40％至60％的银杏叶细胞壁，所述细胞壁内含20nm至100nm直径的天然通道。本技术利用银杏叶细胞壁天然通道，形成有序孔道提升载药容量，松脂酸‑酒石酸分子胶实现肠道靶向释放，避免胃酸破坏与首过效应，丝胶蛋白膜使颗粒在口腔快速崩解，方便起效，天然植物载体全降解无毒性，辊压成型保证颗粒机械强度，防潮且利于长期储存，为患者带来高效、安全、便捷的用药体验。